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Abstract
Novel Coronavirus (nCoV-2019) is a highly infectious viral outbreak that has so 
far infected more than 110 million people worldwide. Fast viral transmission and 
high infection rates have severely affected the entire population, especially the old 
aged and comorbid individuals leaving significantly less time to find some effective 
treatment strategy. In these challenging times, convalescent plasma (CP) therapy 
came as a ray of hope to save humankind. It is a form of passive immunization that 
has been used to treat various infectious diseases since 1890, including the 1918 
Spanish flu, 2002/03 SARS-CoV, 2009 H1N1, 2012 MERS-CoV, and 2014 Ebola 
outbreak. The transfusion includes administration of CP containing a high value of 
neutralizing antibodies against the virus in hospitalized patients. This chapter sum-
marizes the potential outcome of CP therapy in the treatment of nCoV-2019 patients.
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1. Introduction
Convalescent plasma (CP) is defined as a blood plasma that is withdrawn from 
an individual who had encountered some infectious disease and had recovered with 
a required amount of antibodies against the disease [1]. It is a way of passive immu-
nization [2]. The concept has been widely used in medical sciences, especially in the 
case of infectious disease outbreaks. It is an old therapy used since late 1800 [3]. In 
Germany (1890), researchers treated diphtheria patients with sera from immunized 
animals. Afterward, the patients were treated with the sera from the recovered ones 
[4, 5]. The wide use of CP therapy was established during the Spanish influenza 
outbreak between 1918 to 1920 [6]. Humanity faces a great survival challenge 
when a new infectious disease emerges and becomes a pandemic. We do not have 
much to do in such cases, and we mostly rely on our scientific or medical fraternity. 
Therefore, during such a pandemic/epidemic, there is an urgent need to have 
a quick, available therapeutic option [3]. A study estimates that on an average 
basis, there have been 5.3 newly emerged viruses between 1940 to 2004, which 
includes 60–70% of viruses having an animal origin and have potential to the infect 
humans [7]. In such circumstances where there are very few options available for 
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the treatment, and when a patient condition is worsening, CP therapy has always 
been an excellent choice for clinicians. Humans can get exposed to these viruses by 
different means of exposure, and generally, these are considered “unavoidable or 
by chance.” In viruses, the major therapeutic challenges arise because of the high 
degree of genetic changes, which may be due to mutation or genomic instability [8].
In December 2019, a new virus emerged in the Huanan Seafood market and 
resulted in a dreadful outbreak in China, and the virus rapidly spread to more than 
200 countries globally [9]. Further sequence-based analysis of respiratory tract 
samples identified a novel strain, which was distinct from the other known corona-
virus strains, subsequently named Severe Acute Respiratory Syndrome Coronavirus 
2 (SARS-CoV-2), and the disease caused by SARS-CoV-2 infection was designated 
as novel coronavirus-2019 (nCoV-2019) by the World Health Organization (WHO) 
[10]. The emergence of novel coronavirus came up as a big challenge for the con-
cerned authorities of the various country [11]. Clinicians had no clue regarding 
its treatment approaches that made the situation even worse [12]. Soon, on March 
11, 2020, WHO declared it a pandemic. In its initial days, the unavailability of any 
potential drug/therapy resulted in an exponential increase in infections.
For more than a century, this therapy has been widely explored against various 
outbreaks. During the 2002/3 SARS-CoV outbreak, 2012 Middle East Respiratory 
Syndrome (MERS-CoV) outbreak, and H1N1 pandemic (2009), CP therapy was 
successfully explored [13–16]. Similarly, for the 2013/14 Ebola virus infection 
treatment, CP therapy was recommended as an empirical treatment approach 
[17]. Based on previous experiences and similarities in terms of virological and 
clinical characteristics among the SARS-CoV, MERS-CoV, and nCoV-2019 [18], CP 
therapy was explored for its efficacy in the battle against newly emerged (nCoV-
2019) pandemic. In February 2020, for the first time, a group of researchers from 
China reported and published the usefulness of CP in nCoV-2019 severe patients in 
Journals like JAMA [17] and PNAS [16]. CP therapy can be used as a prophylaxis for 
various infectious diseases, primarily when an outbreak occurs.
Many studies showed a significant correlation between CP therapy and improved 
clinical symptoms. In a preliminary study involving 5 critically ill nCoV-2019 
patients, 400 mL CP administration (high neutralizing antibody (NAb) titer >40) 
resulted in improved clinical characteristics [17]. A similar study with 10 critically ill 
patients who received 200 mL of CP (one dose; NAb>1:640) significantly improved 
clinical symptoms within 3 days and viremia resolution within 7 days [16]. Altuntas 
et al. carried out a CP-based study on 888 patients, reported that CP administration 
reduced the ICU stay (p = 0.001) and MV support (p = 0.02) [19]. However, there is 
some uncertainty with large-scale CP transfusion. A PLACID trial published on 464 
patients found that CP therapy did not reduce the progression to severe illness or 
28-day mortality (19% treatment Vs. 18% control group) [20]. A clinical trial on 228 
patients reported no significant benefits in symptoms and overall mortality between 
the intervention (10.93%) and the placebo group (11.43%) [21]. Similarly, a review 
article that studied 20 articles reflected that the efficacy of CP therapy in nCoV-2019 
patients is uncertain [22]. Therefore, the US FDA recommended the use of CP as 
an investigational product [23]. Here, in this chapter, we have explored CP therapy 
potentials on nCoV-2019 based on available literature.
2. Methods
Relevant review search was done using keywords “nCoV-2019 or COVID-19, 
Convalescent Plasma or Plasma therapy”. The search engine included electronic 
databases like PubMed, Google Scholar, and ClinicalTrials.gov.
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3. History of convalescent plasma
This therapy is not new for nCoV-2019, as physicians used this therapy more 
than a century ago [24]. Convalescent plasma has been used historically for a long 
time to develop passive immunity in patients suffering from various bacterial and 
viral diseases such as measles [25], mumps [26], and poliomyelitis [27] by transfer-
ring plasma carrying NAb from previously recovered patients. Although antibiotics 
have replaced CP usage in bacterial diseases, it remains a useful tool for novel viral 
infections for which the vaccine is not available.
A literature study reported that serotherapy was used during the Spanish flu 
(influenza A) pandemic in 1918–1920 for the first time, but this therapy was also 
used before the Spanish flu pandemic [3]. Serotherapy was tried as a therapeutic 
treatment in a poliomyelitis outbreak in New York in 1916 [28]. In 1916 (Tunis), 
some researchers again performed this therapy for the measles [6]. Hess AF in 
1915 applied serotherapy to treat mumps and successfully prevented the testicular 
complications in the affected patients [29]. However, the credit goes to the Italian 
Francesco Cenci, who for the first time used convalescent serum as a therapeutic 
means to save the children that were exposed to measles [30]. Cenci performed 
this experiment by withdrawing 600 mL blood from a patient who recovered from 
measles after 21 days. After that, he administered this therapy to four children aged 
4–8 years [30]. The results were overwhelming as the children did not contract 
measles following the treatment. Since the mortality rate in measles was high, 
ranging from 6–7%, this prophylactic therapy lasted for a long time [31]. There 
was again a measles outbreak in December 1906 in Italy where this therapy was 
administrated in forty sick children, and all the patients recovered successfully. One 
children had severe symptoms, but after therapy, the child showed milder symp-
toms. Luigi Concetti performed a similar therapy in 1900 on two children affected 
with diphtheria in Rome, Italy [6, 32]. After that, CP therapy was used for treating 
many diseases like MERS, Ebola, SARS etc. (Table 1) [33].
During H1N1 influenza epidemics in 2009, CP therapy was given to the patients 
who were in critical conditions and were presented to the hospitals with severe 
respiratory problems. The patients showed reduced viral load in the respiratory 
system and there was also decreased cytokine response and mortality rate [14]. 
CP therapy was also used in the Ebola epidemic in 2013 in West Africa regions 
[34]. SARS-CoV in 2002/2003 and MERS-CoV in 2012, the two outbreaks with 
Disease (epidemic/pandemic) Country Year
Diphtheria Italy 1900
Measles Italy 1906
Mumps (epidemic) USA 1915
Poliomyelitis USA 1916
Measles (epidemic) Tunis 1916
Influenza A (pandemic) Spain 1918
SARS1 (epidemic) China 2002/3
MERS (endemic) Middle East 2012
Ebola (pandemic) West Africa 2013
COVID-19 (pandemic) China 2019
Table 1. 
Use of CP therapy during various diseases outbreak.
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high mortality occurred in early 21st century [35]. In South Korea, MERS became 
endemic, and there was an urgent need for CP therapy as the mortality rate was 
very high, and there was no effective treatment available [35]. Eighty patients of 
SARS-CoV in Hong Kong were given early administration of convalescent plasma, 
and they demonstrated an increased prognosis and got early discharge from the 
hospital [15]. A study in Taiwan showed that the administration of CP in 3 patients 
reduced the viral load [36].
4.  Significance of convalescent plasma therapy during SARS-CoV and 
MERS-CoV outbreaks
Earlier, CP therapy was used to treat similar coronavirus outbreaks, i.e., SARS 
and the MERS in the last two decades (Table 2).
4.1 SARS-CoV outbreak
The first outbreak of the twentieth century that surfaced from China in 2002 led 
to severe respiratory illness and pneumonia-like symptoms in patients. A case study 
published in 2003 reports that CP administration as an adjunctive treatment along-
with ribavirin and prednisolone in a 57-year-old SARS patient on Day 14 reduces 
the viral load and fever within a few days. Further, a better resolution of a basal 
lung infiltrate was seen in chest X-ray post- convalescent plasma treatment [40]. A 
group of Hong-Kong-based researchers, Soo et al. (2004) and Cheng et al. (2005), 
first reported using convalescent plasma as an emergency therapy to contain this 
outbreak. They found that patients treated with steroids and CP had low mortal-
ity and got early discharge from the hospitals compared to patients treated with 
steroids alone [15, 37, 41].
Further, they have found that patients with early administration of convalescent 
plasma (before 14 days of symptoms onset) have shorter hospital stay and have less 
mortality (p = 0.08) than those who received convalescent plasma after 14 days 
[15]. A similar study by Yeh et al. reports about the beneficial effect of CP admin-
istration in SARS infected Health-workers who were severely ill and showed no 
response to available antiviral treatments. The CP administration in them resulted 
in a reduced viral load and fever within a day, followed by resolution of pulmonary 
infiltrates and a time-dependent increase in anti-SARS-CoV IgM and IgG antibod-
ies [36]. In conclusion, early administration of convalescent plasma led to better 
patient outcomes in terms of fast recovery, short hospital stays, reduction in viral 
load, and improvement in clinical symptoms.
4.2 MERS-CoV outbreak
This outbreak took place due to another strain of respiratory illness causing 
coronaviruses, referred to as MERS, pointing to its origin from central-east Asia 
(Arabian countries). From the prior experience of using CP during SARS-CoV 
outbreak, passive immunotherapy by administering NAb in patients serves as 
a vital tool in battle with this disease. Chan et al. in 2012, found that convales-
cent sera of previously recovered SARS patients have cross-reactive NAb that 
can work effectively against novel coronavirus strains [42]. Corti et al. in 2015, 
based on anecdotal evidence, studied the prevalence of MERS specific antibod-
ies in dromedary camels from the middle east (Oman) and European countries 
(Netherland and Chile). They found that all Omanian camels in their study group 
had MERS-CoV-specific NAb in their serum compared to European animals, 
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highlighting the importance of passive immunotherapy upon successfully detect-
ing the transmission source. These antibodies of CP have the potential to neutral-
ize the MERS-CoV if administered in the patients [38]. The effectiveness of CP 
was also reported by van Dorelman et al. in 2017, in common marmosets infected 
with MERS-CoV. They found that marmosets treated with hyperimmune plasma 
and m336 (monoclonal antibodies) showed a reduction in viral load and overall 
severity [39]. However, the use of MERS-CoV antibodies is very challenging, as 
some studies report that they are produced at a low level and are short-lived in 
mild infections [43, 44].
5. Mechanism of action of convalescent plasma
Convalescent plasma to be donated contains specific antibodies for particular 
infectious diseases or pathogens. These antibodies possess neutralization activity. 
This activity is achieved in different ways: either by impeding the binding of viral 
Sr. No. Title of the study Year Indication Outcomes References
1. Retrospective comparison 
of convalescent plasma 
with continuing high-
dose methylprednisolone 
treatment in SARS patients





plasma with no 
adverse effects
[37]
2. Use of convalescent plasma 
therapy in SARS patients in 
Hong Kong
2005 SARS Low mortality 








3. Experience of using 
convalescent plasma for 
severe acute respiratory 
syndrome among healthcare 
workers in a Taiwan hospital









4. Middle East respiratory 
syndrome coronavirus 
neutralising serum 
antibodies in dromedary 
camels: a comparative 
serological study




found in serum 
Omanian camels
[38]
5. Efficacy of antibody-based 
therapies against Middle 
East respiratory syndrome 
coronavirus (MERS-CoV) in 
common marmosets
2017 MERS Reduction 








List of studies describing the significance of CP therapy during SARS-CoV and MERS-CoV outbreaks.
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particles with the endosomes, by hindering the viral protein proteolytic cleavage, by 
blocking the release of viral progeny, or by inhibiting the viral surface glycoproteins 
from invading the human cells [45]. A report published by Lu et al. suggests that 
when a neutralizing antibody (NAb-3BNC117) was passively administered on mice 
model, it helped block NAb helped block the new infection, enhanced clearance of 
the infected cells, and accelerated the HIV-1 infected cell clearance [46].
The other mode of action includes antibody-dependent-cellular-phagocytosis 
(ADCP), complement system activation, and antibody-dependent cellular-
mediated cytotoxicity (ADCC). CP antibodies induce clearance of virus-
infected cells by ADCP. A cross-talk is established among the CP antibodies, 
which helps in eliciting the Fc-dependent effector functions. The activated 
complement system helps eliminate the virus by two means. First, by direct 
means i.e., through complement dependent cytotoxicity. Second, indirect 
means, i.e., by phagocytosis, help clear the associated complement targets. In 
the case of nCoV-2019, the recovered patients may develop serum antibody 
response (IgG) against various virus epitopes [1]. This IgG competes with the 
angiotensin-converting enzyme-2 receptor (ACE-2) to bind with the virus 
receptor-binding domain (RBD) and may neutralize the nCoV-2019 infection. 
Therefore, in this case, the binding domain acts as both, i.e., the epitope for 
antibody and a binding site for the receptor enzyme [2]. Literature suggests 
that when CP therapy is administered at an early stage of nCoV-2019 infection, 
the therapeutic effect may be more effective [47]. In most viral infections, the 
peak of viremia starts appearing in the early first week of the illness. However, 
between days 10–14 or early in some cases, the host primary immune response 
starts exerting its potential effect [47].
6. Use of CP therapy on nCoV-2019 patients
In the absence of any specific treatment of nCoV-2019 and vaccines with 
proven long-term results, CP administration comes to the rescue for an effective 
treatment for critically ill nCoV-2019 patients (Tables 3 and 4). This is a kind of 
passive immunization method where CP from a recovered nCoV-2019 individual is 
obtained and uses them on diseased individuals to resolve the symptoms and reduce 
disease course by suppressing the viremia [18]. The use of passive immunotherapy 
is a widely used approach to combat various infectious diseases, which consisted of 
various formulations such as whole blood, pooled human sera containing immuno-
globulin and convalescent plasma. Plasma collected through apheresis with subse-
quent CP transfusion is the most commonly used passive immunotherapy approach 
to battle against pandemics happened earlier [24]. Theoretically, a person who 
got infected from an infectious disease, upon recovery, blood is screened for NAb 
specific to the causative pathogen suffered earlier. The convalescent plasma con-
taining a high-titer NAb is used as a therapy to maximize the capacity to neutralize 
an infecting pathogen (Figure 1) [56].
Studies from the current nCoV-2019 pandemic suggested that it elicits a robust 
immune response resulting in cytokine storm which generates high levels of IgM 
and IgG mostly that persists for months even after the symptom disappears. 
Thus, a large window period and maximum chances of successful extraction of 
high titer anti-SARS-CoV-2 immunoglobulins act as a boon to utilize it as passive 
immunotherapy [57, 58]. Further studies have elaborated on NAb response. More 
severe disease may lead to higher antibody response levels [58], and antibody level 
decreases considerably within the first 90 days after symptom start among indi-
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al., 2020 [48]




16.1% (95% CI: 
22.1%%)
11 (2.9%) CP administration was found 
to be safe.
2 Retrospective study 
(expanded access)/Joyner et 
al., 2021 [49]
USA (NCT04338360) 3082 — 30 day- 26.9% 
(95% CI: 
25.4–28.5%)
— CP administration in 
hospitalized nCoV-2019 
patients was found to be 
potentially beneficial
3 Case series/Xia et al., 2020 
[50]
China 138 200–1200- mL (based 
on body weight and 
clinical condition)
2.2% -No severe 
transfusion issues
CP transfusion can improve 
the clinical symptoms and 
mortality rate in nCoV-2019 
severe patients
4 Multiceter trial/Abolghasemi 





500 cc - one unit 
(another unit, if 
needed)
14.8% -1 (0.87%) 
(transient mild 
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Early administration of CP 
may be more effective
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2021 [53]









— CP administration may provide 
immediate mortality benefits 














Type of Study (group) Country Sample 
size








7 multicenter randomized, 
double-blind, placebo-
controlled clinical trial/ 
Simonovich VA et al., 2020 
[54]
Argentina (NCT04383535) 333 (228 
CP)
500 mL (IQ range, 
415–600)
30 day-10.96% 11 (4.8% in CP 
group)
CP therapy in COVID-
19 patients with severe 
pneumonia did not reduce 
mortality.
8 Prospective study/ Tworek et 
al., 2020 [55]
Poland 204 (102 
CP)
200 mL (once or more 
depending upon the 
condition)
13.7% — CP therapy was found to be 
safe and effective in high risk 
nCoV-2019 patients
9 multicentre randomised 









adverse events in 
some cases
CP therapy was not relayed 
to the reduction in all-cause 
mortality
Table 4. 
Status of mortality rate after CP administration in hospitalized nCoV-19 patients (studies with sample size >100).
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6.1 Source/donor requirement
In order to overcome various challenges for enrolment of successful plasma 
donors during the outbreak different strategies such as social distancing, travel 
restrictions, and imposed lockdowns have been implemented. To recruit possible 
plasma contributors, this includes donor self-identification, social awareness utiliz-
ing social/formal/e-media outlets and clinician referral of individuals got previous 
exposure to the infection [60]. NAb titres can be examined in possible donor or CP 
units through ELISA/chemiluminescence assay or pseudovirus neutralization assays 
which are known as indirect methods or directly under biosafety level 3 conditions 
by using live SARS-CoV-2 neutralization assays. USFDA has permitted the use of CP 
therapy under the clause of EUA for hospitalised nCoV-2019 infected patients [61]. 
CP units were categorized as lower or higher antibody titre based on qualitative che-
miluminescent immunoassay for detection of neutralizing IgG against SARS-CoV2 
spike protein [60]. The collected plasma is treated for pathogen inactivation to avoid 
the risk of transfusion transmitted infections. A donor can donate CP weekly for 
several months till the antibody titers are high. There are several factors that restrict 
the donation, including the individuals who already received the CP for their nCoV-
2019 treatment (minimum of 90 days) are not allowed to donate blood products.
6.2 Who can donate CP
• Person who has confirmed validated diagnostic record of SARS-CoV-2 infection.
• Physical examination, including the absence of fever and respiratory  
symptoms. Minimum of 14-day post-recovery with no symptoms.
• A person who meets the standard routine blood donation criteria. The donor 
and recipient should be ensured for ABO compatibility
Figure 1. 
Diagrammatic representation of the use of CP in nCoV-2019 patients.
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• CP must be free of HIV, HCV, HBV syphilis, human T-cell lymphotropic virus 
1 and 2, and Trypanosoma cruzi and any other transfusion/locally transmitted 
infections.
• CP from either male donors or from female donors with no pregnancy history 
is preferentially used to avoid any risk of TRALI (Transfusion Related Acute 
Lung Injury) [62].
• For retrospective testing and scientific investigations, donors blood products 
(serum, plasma, whole blood) should be saved at −800 C.
6.3 Plasma donation
Convalescent plasma donors may be identified during national disease-specific 
cohorts, during hospitalization of the patient, by the practitioners treating outpa-
tients, and through various specific online/social helpline-networks.
6.3.1 FDA guidelines
The FDA recommends three approaches for the administration of CP. First is 
directed for the treatment of patients of nCoV-2019 through EUA. Second, patients 
with severe nCoV-2019 illness who are unable to participate in RCT through 
expanded access protocol. The third one involves clinical trials where clinicians are 
advised to enroll patients in the trials to examine the effectiveness of CP therapy in 
nCoV-2019 [63].
6.4 Dosage
Various dosage regimens were utilized in various hospital setups for the manage-
ment of SARS-CoV2 infected patients. Universally 200 ml of convalescent plasma 
in 1 or 2 doses with an infusion rate of 100 to 200 ml/h are administered with an 
interval of 12 hr. apart. The dosage regimen is decided according to body weight 
and antibody titer [64]. Standard hospital procedures and recommendations should 
be followed for thawing and transfusion of plasma through a peripheral or central 
venous catheter.
6.5 Follow up
CP therapy is still an experimental model. For future scientific investigations 
and correlations, the blood products of the recipient should be stored (prior and 
after transfusion). As per published trials, the response post CP therapy is mainly 
assessed i.e., PaO2/FiO2 ratio clinically or through Ct scan or X-ray (radiological) 
of the infected organ. However, elicitation of nCoV-2019 antibody titer or increased 
ALC in recipients, as well as a decline in SARS-CoV2 viral load either in terms of 
absolute quantification or increase of cycle threshold (Ct) value, could be consid-
ered as surrogate endpoints [65].
7. Risk associated with the use of CP therapy
Major adverse events associated with CP transfusion are not much evident so far. 
However, risk assessment before/after the transfusion is important. Several stud-
ies/clinical trials have shown that the use of CP therapy in severely ill nCoV-2019 
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patients is safe and early administration with adequate anti-SARS-CoV-2-NAb 
titer is helpful in faster recovery and survival of nCoV-2019 patients [18, 66]. CP 
therapy is contraindicated in certain individuals such as those who are allergic to 
plasma protein or sodium citrate, patients with selective IgA deficiency (70 mg/
dl in patients four years old or older), or the ones who received treatment with 
immunoglobulins in the last 30 days as it could lead to the development of serum 
sickness [67].
However, large U.S. national registry, through its interim report, showed that 
among over 100,000 hospitalized adults that had nCoV-2019 infection, low inci-
dences of transfusion reactions were documented in the first 5,000, and 20,000 
patients transfused with nCoV-2019 CP therapy, which is suggestive of the fact that 
transfusion of convalescent plasma is safe and poses no additional risk of complica-
tions among hospitalized patients with nCoV-2019 [52, 68]. An RCT compared the 
safety of convalescent plasma transfusion with fresh frozen plasma transfusion 
documented a comparatively less rates between the controls (7%) and CP (4%) 
group of patients and highlighted the safety profile of CP transfusion [69].
8. Conclusions
In the absence of any effective antiviral drug and vaccine (long term effect is not 
yet established) to prevent the infection, several approaches have been explored to 
reduce the duration of the disease course. One therapeutic approach that is being 
utilized globally is convalescent plasma therapy against nCoV-2019. Once the 
person recovers from nCoV-2019, the blood contains antibodies against the caus-
ative virus. In emergency situations, these antibodies can be given to other affected 
people to provide immediate immunity against the virus, reducing the severity and 
helping in faster recovery. FDA has not yet approved the use of CP as a treatment of 
nCoV-2019. It is administered under the EUA or an IND. However, further large-
scale, world-wide controlled clinical trials are needed to prove the efficacy of the CP 
therapy for the current pandemic.
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